Drug intelligence / Profile preview

2'-fucosyllactose + lactoneotetraose

Development stage
Unknown
Lead developer
Chr. Hansen
Modality
Microbiome-Derived Products → Microbiome Therapeutics
Administration
Oral
01

Overview

**2'-fucosyllactose + lactoneotetraose** is a combination of two human milk oligosaccharides (HMOs): 2'-fucosyllactose (2'-FL), a neutral trisaccharide consisting of L-fucose, D-galactose, and D-glucose, and lactoneotetraose (more precisely, "lacto-N-neotetraose" or LNnT), a neutral tetrasaccharide consisting of D-galactose, N-acetyl-D-glucosamine, D-galactose, and D-glucose[1][3]. These oligosaccharides are naturally found in human breast milk and are among the most abundant HMOs present[1][3]. In infant formula, this combination is designed to mimic the composition and potential health benefits of breast milk for infants who cannot be breastfed. Mechanistically, 2'-FL and LNnT are indigestible by the upper gastrointestinal tract and reach the colon, where they serve as prebiotics—promoting the growth of beneficial gut bacteria such as bifidobacteria[3]. They also act as soluble decoy receptors, blocking the adhesion of pathogens to epithelial cells, thereby reducing infection risk[1][3]. Administration in infant formula has been shown to be safe and well tolerated in infants, with possible benefits for immune modulation (such as lower plasma inflammatory cytokine levels) and gut microbiota similar to that of breastfed infants[2][3]. This combination is not considered a pharmaceutical or conventional drug but rather a functional ingredient or dietary supplement, primarily regulated for use in infant foods[2][3][4].

Other names
2'-FL + LNnT2'-fucosyllactose + lacto-N-neotetraose
02

Targets

CD14 (Monocyte differentiation antigen CD14)

Beyond the preview

Go deeper on 2'-fucosyllactose + lactoneotetraose.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on 2'-fucosyllactose + lactoneotetraose.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call